Prenzel F, Pfäffle R, Thiele F, Schuster V
Clinic for Pediatric and Adolescent Medicine, University Hospitals of Leipzig.
Klin Padiatr. 2006 May-Jun;218(3):174-6. doi: 10.1055/s-2006-933401.
In patients with Henoch-Schoenlein purpura (HSP), particularly with severe gastrointestinal symptoms, an associated decrease of plasma factor XIII has been observed.
The authors report a case of HSP in a boy and describe the development of factor XIII activities throughout the course of the disease. Every relapse of severe gastrointestinal manifestation was associated with a decrease of factor XIII. No improvement was seen after treatment with prednisone. The symptoms resolved each time factor XIII concentrate was administered. With the return of factor XIII to normal values eight weeks after admission abdominal symptoms ceased.
The documented course supports the hypothesis that factor XIII activity correlates well with the severity of abdominal symptoms. Measuring factor XIII activity helps to identify those patients with severe gastrointestinal manifestation who may benefit from substitution therapy.
在过敏性紫癜(HSP)患者中,尤其是伴有严重胃肠道症状的患者,已观察到血浆因子 XIII 水平下降。
作者报告了一名患过敏性紫癜的男孩病例,并描述了疾病过程中因子 XIII 活性的变化。每次严重胃肠道症状复发都与因子 XIII 水平下降有关。使用泼尼松治疗后未见改善。每次给予因子 XIII 浓缩物后症状均缓解。入院八周后因子 XIII 恢复至正常水平,腹部症状消失。
记录的病程支持以下假设,即因子 XIII 活性与腹部症状的严重程度密切相关。检测因子 XIII 活性有助于识别那些可能从替代治疗中获益的有严重胃肠道表现的患者。